Nature:羊毛甾醇(Lanosterol)滴眼液可能用于白内障的治疗

2015-07-25 MedSci MedSci原创

在Nature杂志上,加利福尼亚大学圣地亚哥分校(UCSD)的一个研究表明,一种含有羊毛甾醇的溶液是如何通过滴眼液的形式减轻狗的白内障症状的。晶状体大部分是由晶状体球蛋白组成的,主要作用是改变焦点和保持视野清晰。但是我们并不确切地知道相关的作用原理。当晶状体蛋白的结构被破坏后,它们凝结呈块状,使晶状体混浊,因此导致患者出现白内障。晶状体富含一种微粒叫羊毛甾醇(羊毛甾醇由羊毛甾醇合成酶合成),这种微

在Nature杂志上,加利福尼亚大学圣地亚哥分校(UCSD)的一个研究表明,一种含有羊毛甾醇的溶液是如何通过滴眼液的形式减轻狗的白内障症状的。


晶状体大部分是由晶状体球蛋白组成的,主要作用是改变焦点和保持视野清晰。但是我们并不确切地知道相关的作用原理。

当晶状体蛋白的结构被破坏后,它们凝结呈块状,使晶状体混浊,因此导致患者出现白内障。晶状体富含一种微粒叫羊毛甾醇(羊毛甾醇由羊毛甾醇合成酶合成),这种微粒是机体内许多重要激素的重要组成部分。

研究人员开始研究羊毛甾醇,是因为他们发现所有的先天性白内障儿童都由有阻断羊毛甾醇合成酶的基因突变。

他们有一种预感,也许正常的眼睛(即晶状体内的羊毛甾醇很丰富)中,某些物质如羊毛甾醇可避免促使白内障形成的相关蛋白质凝结成块。

研究人员进行了三组实验,不仅对实验室细胞进行了研究,也在动物身上进行了实验。

首先,研究人员在人的晶状体细胞中发现羊毛甾醇可以减轻一些蛋白质凝结成块的作用,这些蛋白质可促使白内障的产生;然后,研究人员发现使用羊毛甾醇治疗有白内障和晶状体透明度增加的兔子后,它们的视力症状有所减轻。

最后,当他们对患有白内障的狗通过注射或者使用滴眼液的形式给予羊毛甾醇溶液后,狗的视力症状也有所减轻,且在减少蛋白质聚集方面同人晶状体细胞和兔晶状体一样:白内障症状减轻,视野更加清晰。

研究人员得出结论:羊毛甾醇在预防和治疗白内障方面起到至关重要的作用,它是一种新型的白内障预防和治疗策略。

滴眼液中含有羊毛甾醇成分被证明是一种有效的治疗白内障的方法。截至目前,唯一根治白内障的方法是手术治疗。但这不是适用于所有人。据世界卫生组织(WHO)的相关调查表明,在许多国家,有许多患者因为各种原因无法采用白内障手术进行治疗,因此白内障仍然是导致失明的主要原因。该研究就为那些无法采取手术的白内障患者带来了福音。在未来的生活中,白内障患者或许不用手术,采用羊毛甾醇进行治疗即可恢复视力。

原始出处:

Zhao L, Chen XJ, Zhu J, Xi YB, Yang X, Hu LD, Ouyang H, Patel SH, Jin X, Lin D, Wu F, Flagg K, Cai H, Li G, Cao G, Lin Y, Chen D, Wen C, Chung C, Wang Y, Qiu A, Yeh E, Wang W, Hu X, Grob S, Abagyan R, Su Z, Tjondro HC, Zhao XJ, Luo H, Hou R, Jefferson J, Perry P, Gao W, Kozak I, Granet D, Li Y, Sun X, Wang J, Zhang L, Liu Y, Yan YB, Zhang K. Lanosterol reverses protein aggregation in cataracts. Nature. 2015 Jul 22. doi: 10.1038/nature14650

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-01-16 medsic

    嗯,不错,

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-01-16 medsic

    嗯,不错,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-01-16 medsic

    又有新药了,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-01-16 medsic

    又有新药了,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2015-09-17 liye789132251
  8. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2016-06-27 xsm928
  9. [GetPortalCommentsPageByObjectIdResponse(id=59812, encodeId=6672598129e, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59813, encodeId=86cf59813ad, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:56:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57812, encodeId=ca695e812fb, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57813, encodeId=847c5e81338, content=嗯,不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=206, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57814, encodeId=210e5e814f2, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=57815, encodeId=2ee15e815ce, content=又有新药了,, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 16 00:40:00 CST 2016, time=2016-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1880748, encodeId=1bbe1880e4814, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 17 23:56:00 CST 2015, time=2015-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705112, encodeId=bf291e0511284, content=<a href='/topic/show?id=a04166612d3' target=_blank style='color:#2F92EE;'>#滴眼液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66612, encryptionId=a04166612d3, topicName=滴眼液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62d830929644, createdName=xsm928, createdTime=Mon Jun 27 22:56:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=33488, encodeId=9258334884e, content=这可能运一些新药的研发吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sat Jul 25 22:41:00 CST 2015, time=2015-07-25, status=1, ipAttribution=)]
    2015-07-25 lovetcm

    这可能运一些新药的研发吧

    0

相关资讯

Cell Stem Cell:中科院用CRISPR技术治愈小鼠白内障

中科院上海生物化学与细胞生物学研究所李劲松研究组在一项最新研究中,利用CRISPR-Cas9技术,治愈了小鼠的白内障遗传疾病。专家认为,这项实验为人类基因治疗提供了一条新思路。12月5日,相关成果在线发表于《细胞—干细胞》杂志。中科院李劲松博士同时,该成果被国际杂志《科学家》选择进行同期新闻发布。CRISPR-Cas9技术是利用一段与靶序列相同的单导向RNA(sgRNA)来引导Cas9核酸酶对特异

Structure :αB-Crystallin在白内障的形成中起关键作用

在一项突破性研究中,来自加州大学欧文分校(UC Irvine)等机构的科学家破译了白内障形成的分子机制,这一发现将有助开发出治疗白内障的新方法。白内障是全世界致人失明的主要原因。当前,它影响着全世界将近 2 千万人。“这是人类的梦想,我们已向前迈出一大步,”论文主要作者、加州大学欧文分校化学副教授 Rachel Martin 表示,“理解眼睛中是发生什么差错而导致白内障产生的分子机制,可能会开发出

手术医师的目标:白内障术后无散光并保持屈光状态稳定

随着白内障手术和屈光手术结合日益紧密,为了使患者术后脱镜并拥有优异的视力,我们将更关注角膜散光的处理。我们的目的是获得无散光的屈光状态(可能与标准角膜曲率计不会完全吻合),并希望这种屈光状态能持续稳定多年。休斯敦贝勒医学院眼科专家们最近的研究对达到以上目的,并优化白内障术后屈光效果起到了指导作用。角膜散光随时间变化一个10年前曾行白内障手术的患者再次回到诊室复诊,值得注意的是他的远视力呈逐年下降的

JCRS:白内障术后疗效满意度相关因素调查

白内障手术旨在改善患者视力、提高患者生活质量,但仅仅将视力检测作为唯一评估手术效果的指标是远远不够的,更重要的是患者自觉的视功能改善及手术效果、满意度。如何做漂亮手术,提高患者主观满意度是每位术者的终极目标。 对瑞典41家白内障中心术后患者的断面研究显示:无并发眼病、年轻、女性、等候手术时间短、术前视力差、术后视力好的白内障患者自觉视功能改善更明显;术前无并发眼病、术后矫正远视力(CDVA)好的

体力活动或能减少白内障发病风险

长期的总的体力活动水平,特别是某些特殊类型的活动,能减少年龄相关性白内障的发病风险,相关研究发布在最新一期ophthalmology上。 总共有52660人(年龄从45岁-83岁)完成了问卷调查,作为两个大型以人群为基础的队列研究的一部分,该调查的目的是评价体力活动与白内障的关系。在随访的12年间,11580人发生了年龄相关性白内障。 在排除了其它因素的影响之后(比如水果和蔬菜摄入,抗氧化补充

ESC 2013:他汀类药物可降低白内障风险50%

8月31日,ESC 2013大会上美国John B. Kostis教授公布的一项新研究显示,他汀类药物可使白内障发生率降低20%。在治疗疗程较长的年轻(40岁)人群中,他汀类药物能使白内障的发生风险降低50%。